Innovus Pharmaceuticals Inc (INNV) 0.1900 $INNV
Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
ACCESSWIRE - Thu Dec 18, 7:14AM CST
Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
Innovus Pharma Expands Agreement with Tramorgan Limited to Commercialize Vesele(R) in the United Kingdom
ACCESSWIRE - Thu Dec 11, 9:54AM CST
Innovus Eligible to Receive up to $13 Million in Sales Milestone Payments plus 50% Royalties on Sales of Vesele(R)
Innovus Pharmaceuticals to Present at LD Micro Conference in Los Angeles on December 2, 2014
ACCESSWIRE - Wed Nov 26, 5:00AM CST
San Diego, CA / ACCESSWIRE / November 26, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
, (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it will be presenting at the LD Micro Conference held in Los Angeles, CA from December 2 - 4, 2014.
Innovus Pharmaceuticals Announces a 77% Achievement of Increase in Arousal from a 246 Use Survey Study in British Women that Used Zestra(R)
ACCESSWIRE - Tue Nov 25, 5:02AM CST
San Diego, CA / ACCESSWIRE / November 25, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health and vitality announced today a positive analysis and outcome of a 246 use survey study in the United Kingdom for Zestra(R) in women, conducted by Semprae Laboratories prior to its acquisition by Innovus Pharma, but never reported. In this use survey study, 246 women, including a large number of nurse practitioners between the ages of 30-60 years old, used Zestra(R) over a period of two weeks. Users were asked to answer a modified diary of the FSFI score.
Innovus Pharmaceuticals Provides Third Quarter 2014 Financial Results With Commercial and Corporate Update
ACCESSWIRE - Fri Nov 14, 11:30AM CST
Revenues Up by 289% to $443,087 for Third Quarter 2014 Compared to Second Quarter 2014
Innovus Pharmaceuticals Announces Its Revenue Guidance
ACCESSWIRE - Wed Nov 05, 5:16AM CST
San Diego, CA / ACCESSWIRE / November 5, 2014 / Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a provider for over the counter men's and women's health products, will release its third quarter 2014 financial results on Friday, November 14, 2014 when it expects to file its Form 10-Q for the 2014 third quarter.
Innovus Pharma CEO, Dr. Bassam Damaj, Featured on Wide World of Stocks Television
ACCESSWIRE - Mon Nov 03, 11:02AM CST
Interview with Dr. Damaj highlights Commercial Products for Men's and Women's Health, Recent Company Milestones Achieved, and Long Term Domestic and International Growth Strategy
Innovus Announces the Acquisition of Vesele(R), A Safer Proprietary Oral Formualtion to Maximize Nitric Oxide's Beneficial Effects on Sexual Function and Brain Health
ACCESSWIRE - Tue Oct 28, 5:01AM CDT
SAN DIEGO, CA / ACCESSWIRE / October 28, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCBB: INNV) announced today the acquisition of Vesele(R) from TrAphikAs, Inc., a company located in Florida. Vesele(R) is a proprietary, novel and safer oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele(R) contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R).
Innovus Pharmaceuticals Receives Approval for the Expanded Label Indication for its Zestra(R) Product in Canada for the Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder
ACCESSWIRE - Fri Oct 24, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / October 24, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTC: BB: INNV) today announced that it has received approval from Health Canada for an expanded label for its marketed Zestra(R) product. Zestra(R) is currently approved and marketed in Canada for the indication of "Temporary Increase of Desire in Female Sexual Desire Disorder Women ("FSDD" ". The new indication approved is expanded to that of "Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder" ("FSI/AD" .
Innovus Pharma Announces Podium Presentation at the World Meeting of Sexual Medicine, Discussing the Clinical Efficacy of Zestra(R) in Cancer Patients
GlobeNewswire - Thu Oct 02, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV) announced today the selection of an oral podium presentation of Zestra(R), its clinically proven topical product to increase female sexual arousal and desire entitled, "Female Arousal and Orgasmic Complaints in a Diverse Cancer Population Treated with Zestra(R): A Topical Applied Blend of Oils", at the World Meeting on Sexual Medicine, which will take place in Sao Paulo, Brazil, from October 8 to 12, 2014. The podium presentation will be given by Dr. Michael Krychman and is scheduled under The Arousal and Desire session on Thursday, October 9, 11:30 am - 12:30 pm. Innovus will also exhibit two posters. The moderated poster entitled "Treatment Paradigm for Women with Arousal and Orgasmic Complaints", under the Women's Sexual Medicine session is scheduled for presentation on Saturday, October 11, 14:00 - 15:30 hrs. The non-moderated poster presentation entitled "Female Arousal and Orgasmic Complaints in a Diverse Female Population with Multiple Medical Issues Treated with Zestra(R)" will be exhibited digitally for the duration of the meeting from October 8 to 12, 2014.
SeeThruEquity Initiates Research Coverage on Innovus Pharmaceuticals, Inc. with a Target Price of $1.34
ACCESSWIRE - Mon Sep 29, 8:01AM CDT
New York, NY / ACCESSWIRE / September 29, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Innovus Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicines and consumer care products to improve men's and women's health and vitality.
Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West Africa
GlobeNewswire - Wed Sep 24, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCBB:INNV) announced today it has entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan company (SOT.CSE) ("Sothema" under which Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSDD" , Zestra(R) and its high viscosity water-based lubricant Zestra Glide(R) in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates (excluding Lebanon and Israel) and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the "Territory" . Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit.
Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in Canada
GlobeNewswire - Mon Sep 22, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a license agreement with Orimed Pharma ("Orimed" , an affiliate of JAMP Pharma, under which Innovus Pharma granted to Orimed an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder("FSDD" , Zestra(R), its topical treatment for premature ejaculation, EjectDelay(TM), its product Sensum+(TM) (previously called CIRCUMSerum(TM)) to increase penile sensitivity and its high viscosity water based lubricant, Zestra Glide(R) in Canada. Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed's cumulative net sales in Canada.
Innovus Pharma to market and distribute Sensum+ in the UK through Tramorgan
M2 - Thu Sep 18, 6:12AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) reported on Thursday the grant of an exclusive marketing sales and distribution right to its topical consumer care product Sensum+ in the UK to UK based Tramorgan.
Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom
GlobeNewswire - Thu Sep 18, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV) announced today that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company ("Tramorgan" under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+(TM) in the United Kingdom ("UK" . The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets.
Innovus Pharmaceuticals signs non-exclusive sampling, marketing and distribution agreement for Zestra in the US
M2 - Tue Sep 09, 6:42AM CDT
Innovus Pharmaceuticals (Other OTC:INNV), a provider of sexual dysfunction products, revealed on Monday the launch of an non-exclusive sampling, marketing and distribution agreement for Zestra with Bulu Bo.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV), Exclusive Interview for Interlinked's Investment News Channel
PRWeb - Mon Sep 08, 6:05AM CDT
Innovus Pharma was one of the presenting companies at the recent FSXinterlinked Investment Conference, held at the Four Seasons Hotel in Westlake Village, California.
Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US
GlobeNewswire - Mon Sep 08, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box(R) ("Bulu Box" under which Bulu Box will add Zestra(R) as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra(R) 3 packettes box through its E-commerce platform in the US.
Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New York
GlobeNewswire - Thu Sep 04, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.
Innovus Pharma to market and distribute Zestra for alternative markets through DanaLife ApS
M2 - Thu Aug 28, 6:56AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) Thursday executed an exclusive marketing and distribution agreement to grant the worldwide distribution right (excluding Canada) to market and sell its topical consumer care product Zestra in the alternative markets that excludes all medical and mainstream sales channels.
Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
ACCESSWIRE - Thu Dec 18, 7:14AM CST
Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
Innovus Pharma Expands Agreement with Tramorgan Limited to Commercialize Vesele(R) in the United Kingdom
ACCESSWIRE - Thu Dec 11, 9:54AM CST
Innovus Eligible to Receive up to $13 Million in Sales Milestone Payments plus 50% Royalties on Sales of Vesele(R)
Innovus Pharmaceuticals to Present at LD Micro Conference in Los Angeles on December 2, 2014
ACCESSWIRE - Wed Nov 26, 5:00AM CST
San Diego, CA / ACCESSWIRE / November 26, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
, (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it will be presenting at the LD Micro Conference held in Los Angeles, CA from December 2 - 4, 2014. Innovus Pharmaceuticals Announces a 77% Achievement of Increase in Arousal from a 246 Use Survey Study in British Women that Used Zestra(R)
ACCESSWIRE - Tue Nov 25, 5:02AM CST
San Diego, CA / ACCESSWIRE / November 25, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC" and consumer products for men's and women's health and vitality announced today a positive analysis and outcome of a 246 use survey study in the United Kingdom for Zestra(R) in women, conducted by Semprae Laboratories prior to its acquisition by Innovus Pharma, but never reported. In this use survey study, 246 women, including a large number of nurse practitioners between the ages of 30-60 years old, used Zestra(R) over a period of two weeks. Users were asked to answer a modified diary of the FSFI score. Innovus Pharmaceuticals Provides Third Quarter 2014 Financial Results With Commercial and Corporate Update
ACCESSWIRE - Fri Nov 14, 11:30AM CST
Revenues Up by 289% to $443,087 for Third Quarter 2014 Compared to Second Quarter 2014
Innovus Pharmaceuticals Announces Its Revenue Guidance
ACCESSWIRE - Wed Nov 05, 5:16AM CST
San Diego, CA / ACCESSWIRE / November 5, 2014 / Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a provider for over the counter men's and women's health products, will release its third quarter 2014 financial results on Friday, November 14, 2014 when it expects to file its Form 10-Q for the 2014 third quarter.
Innovus Pharma CEO, Dr. Bassam Damaj, Featured on Wide World of Stocks Television
ACCESSWIRE - Mon Nov 03, 11:02AM CST
Interview with Dr. Damaj highlights Commercial Products for Men's and Women's Health, Recent Company Milestones Achieved, and Long Term Domestic and International Growth Strategy
Innovus Announces the Acquisition of Vesele(R), A Safer Proprietary Oral Formualtion to Maximize Nitric Oxide's Beneficial Effects on Sexual Function and Brain Health
ACCESSWIRE - Tue Oct 28, 5:01AM CDT
SAN DIEGO, CA / ACCESSWIRE / October 28, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCBB: INNV) announced today the acquisition of Vesele(R) from TrAphikAs, Inc., a company located in Florida. Vesele(R) is a proprietary, novel and safer oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele(R) contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R). Innovus Pharmaceuticals Receives Approval for the Expanded Label Indication for its Zestra(R) Product in Canada for the Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder
ACCESSWIRE - Fri Oct 24, 5:00AM CDT
SAN DIEGO, CA / ACCESSWIRE / October 24, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTC: BB: INNV) today announced that it has received approval from Health Canada for an expanded label for its marketed Zestra(R) product. Zestra(R) is currently approved and marketed in Canada for the indication of "Temporary Increase of Desire in Female Sexual Desire Disorder Women ("FSDD" ". The new indication approved is expanded to that of "Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder" ("FSI/AD" . Innovus Pharma Announces Podium Presentation at the World Meeting of Sexual Medicine, Discussing the Clinical Efficacy of Zestra(R) in Cancer Patients
GlobeNewswire - Thu Oct 02, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV) announced today the selection of an oral podium presentation of Zestra(R), its clinically proven topical product to increase female sexual arousal and desire entitled, "Female Arousal and Orgasmic Complaints in a Diverse Cancer Population Treated with Zestra(R): A Topical Applied Blend of Oils", at the World Meeting on Sexual Medicine, which will take place in Sao Paulo, Brazil, from October 8 to 12, 2014. The podium presentation will be given by Dr. Michael Krychman and is scheduled under The Arousal and Desire session on Thursday, October 9, 11:30 am - 12:30 pm. Innovus will also exhibit two posters. The moderated poster entitled "Treatment Paradigm for Women with Arousal and Orgasmic Complaints", under the Women's Sexual Medicine session is scheduled for presentation on Saturday, October 11, 14:00 - 15:30 hrs. The non-moderated poster presentation entitled "Female Arousal and Orgasmic Complaints in a Diverse Female Population with Multiple Medical Issues Treated with Zestra(R)" will be exhibited digitally for the duration of the meeting from October 8 to 12, 2014. SeeThruEquity Initiates Research Coverage on Innovus Pharmaceuticals, Inc. with a Target Price of $1.34
ACCESSWIRE - Mon Sep 29, 8:01AM CDT
New York, NY / ACCESSWIRE / September 29, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Innovus Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicines and consumer care products to improve men's and women's health and vitality.
Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West Africa
GlobeNewswire - Wed Sep 24, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCBB:INNV) announced today it has entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan company (SOT.CSE) ("Sothema" under which Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSDD" , Zestra(R) and its high viscosity water-based lubricant Zestra Glide(R) in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates (excluding Lebanon and Israel) and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the "Territory" . Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit. Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in Canada
GlobeNewswire - Mon Sep 22, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a license agreement with Orimed Pharma ("Orimed" , an affiliate of JAMP Pharma, under which Innovus Pharma granted to Orimed an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder("FSDD" , Zestra(R), its topical treatment for premature ejaculation, EjectDelay(TM), its product Sensum+(TM) (previously called CIRCUMSerum(TM)) to increase penile sensitivity and its high viscosity water based lubricant, Zestra Glide(R) in Canada. Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed's cumulative net sales in Canada. Innovus Pharma to market and distribute Sensum+ in the UK through Tramorgan
M2 - Thu Sep 18, 6:12AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) reported on Thursday the grant of an exclusive marketing sales and distribution right to its topical consumer care product Sensum+ in the UK to UK based Tramorgan.
Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom
GlobeNewswire - Thu Sep 18, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV) announced today that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company ("Tramorgan" under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+(TM) in the United Kingdom ("UK" . The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets. Innovus Pharmaceuticals signs non-exclusive sampling, marketing and distribution agreement for Zestra in the US
M2 - Tue Sep 09, 6:42AM CDT
Innovus Pharmaceuticals (Other OTC:INNV), a provider of sexual dysfunction products, revealed on Monday the launch of an non-exclusive sampling, marketing and distribution agreement for Zestra with Bulu Bo.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV), Exclusive Interview for Interlinked's Investment News Channel
PRWeb - Mon Sep 08, 6:05AM CDT
Innovus Pharma was one of the presenting companies at the recent FSXinterlinked Investment Conference, held at the Four Seasons Hotel in Westlake Village, California.
Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US
GlobeNewswire - Mon Sep 08, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box(R) ("Bulu Box" under which Bulu Box will add Zestra(R) as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra(R) 3 packettes box through its E-commerce platform in the US. Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New York
GlobeNewswire - Thu Sep 04, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.
Innovus Pharma to market and distribute Zestra for alternative markets through DanaLife ApS
M2 - Thu Aug 28, 6:56AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) Thursday executed an exclusive marketing and distribution agreement to grant the worldwide distribution right (excluding Canada) to market and sell its topical consumer care product Zestra in the alternative markets that excludes all medical and mainstream sales channels.
